LG Unveils Revolutionary AI Model for Rapid Cancer Diagnosis and Treatment
July 9, 2025
LG AI Research has launched EXAONE Path 2.0, an upgraded pathology AI model that significantly improves accuracy in analyzing human tissue images and predicting genetic mutations and gene expression patterns.
Exemplary Pass 2.0, part of LG's next-generation AI models, can predict gene activity solely through image analysis, reducing testing time from over two weeks to less than a minute, enabling faster cancer diagnosis and treatment decisions.
LG Group has introduced 'Exemplar Pass 2.0' to enhance early diagnosis, prognosis prediction, and personalized treatment, especially for cancer, marking a major step forward in precision medicine.
The new AI model integrates multiomics data, including DNA and RNA, achieving a world-leading 78.4% accuracy in predicting genetic mutations by learning from small units of whole slide images, overcoming previous limitations.
This AI can analyze high-quality tissue and genetic data rapidly, assisting doctors and pharmaceutical companies in identifying mutations and targeted treatments for cancer patients.
Medical professionals and pharma firms can use this AI to quickly analyze tissue images, identify gene mutations, and select targeted therapies, accelerating personalized cancer treatment.
The model has been trained on over 10,000 datasets, pairing whole slide images with multiomics data, enabling gene activity prediction solely through image analysis and eliminating the need for costly genomic tests.
LG is actively engaging in global collaborations, including efforts with Jackson Lab to discover Alzheimer's factors and with Seoul National University to develop protein structure prediction AI, while seeking new drug development partnerships worldwide.
Following the retirement of Baek Sung-hoon, LG is in the process of appointing a new leader focused on strengthening its AI capabilities and achieving major breakthroughs in AI technology.
Exemplary Pass 2.0 will be showcased at the 'LG AI Talk Concert 2025' on July 22, highlighting its potential to revolutionize medical AI and serve as a game changer in healthcare technology.
LG is collaborating with Vanderbilt University Medical Center on a multimodal medical AI platform that integrates AI with molecular biology, aiming to revolutionize drug discovery, cancer research, transplant science, and precision medicine.
This platform is expected to streamline the entire process of drug development and treatment, with ongoing development of specialized AI models for diseases like lung and colon cancer to facilitate early screening.
Summary based on 4 sources
Get a daily email with more AI stories
Sources

korea joongAng daily • Jul 9, 2025
LG AI Research launches upgraded AI model Exaone Path 2.0 to improve cancer diagnosis, treatment options
Yonhap News Agency • Jul 9, 2025
LG unveils improved pathology AI model, EXAONE Path 2.0